64 results
8-K
EX-1.1
SLNO
Soleno Therapeutics Inc
7 May 24
Soleno Therapeutics Announces Pricing of Approximately $138 Million Public Offering of Common Stock
5:28pm
. Neither the Company nor any Subsidiary has received notice of any investigation or proceedings which, if decided adversely to the Company … knowledge, threatened administrative, regulatory or judicial action, claim or notice of noncompliance or violation, investigation or proceedings
8-K
EX-1.1
SLNO
Soleno Therapeutics Inc
29 Sep 23
Entry into a Material Definitive Agreement
4:55pm
as could not reasonably be expected to have a Material Adverse Effect. Neither the Company nor any Subsidiary has received notice of any investigation … or notice of noncompliance or violation, investigation or proceedings relating to any Environmental Law against the Company or any Subsidiary, except
8-K
EX-1.1
SLNO
Soleno Therapeutics Inc
26 Jun 20
Soleno Therapeutics Announces Pricing of $50 Million Public Offering of Common Stock
4:31pm
a Material Adverse Effect. Neither the Company nor any Subsidiary has received notice of any investigation or proceedings which, if decided adversely … or notice of noncompliance or violation, investigation or proceedings relating to any Environmental Law against the Company or any Subsidiary, except in each
8-K
EX-1.1
SLNO
Soleno Therapeutics Inc
25 Oct 19
Soleno Therapeutics Announces Pricing of $13.4 Million Public Offering of Common Stock
4:03pm
and shall be responsible for making its own independent investigation and appraisal of the transactions contemplated hereby, and the Underwriters shall … . The Company has consulted with its own advisors concerning such matters and shall be responsible for making its own independent investigation and appraisal
8-K
EX-4.1
SLNO
Soleno Therapeutics Inc
27 Jul 15
Capnia Announces $10 Million At-the-Market Firm Commitment Stock Purchase Agreement with Aspire Capital
12:00am
, preparing or defending any action, claim, suit, inquiry, proceeding, investigation or appeal taken from the foregoing by or before any court … in full force and effect regardless of any investigation made by or on behalf of the Indemnified Person and shall survive the transfer
8-K
EX-99.1
d9xg1
15 Mar 19
Other Events
9:56pm
S-1/A
EX-10.19
v47jlh
1 Jul 14
IPO registration (amended)
12:00am
8-K
EX-1.1
qm3 4544arpg4g8j3u
30 Mar 22
Soleno Therapeutics Announces Pricing of Approximately $15 Million Underwritten Public Offering
5:24pm
8-K
EX-1.1
whronk t3rf
16 Jul 21
Entry into a Material Definitive Agreement
4:14pm
8-K
EX-99.1
gyng8 e70tr
6 Jan 20
Soleno Therapeutics Completes Target Enrollment in Ongoing DESTINY PWS Phase III Trial of DCCR in Prader Willi Syndrome
5:01pm
8-K
EX-10.1
0gdzk pgums6
19 Dec 18
Soleno Therapeutics Announces $16.5 Million Private Placement
4:02pm
8-K
EX-10.1
zgsdfz6o3ht25pyss5
19 Dec 22
Soleno Therapeutics Announces Financing Commitment for up to $60 Million
4:49pm
8-K
EX-10.1
rxnp6e55gti l5cv
29 Sep 23
Entry into a Material Definitive Agreement
4:55pm
424B3
i2v7na
14 Oct 15
Prospectus supplement
12:00am
424B3
w42jry9 yh
24 Jul 17
Prospectus supplement
12:00am
S-3ASR
EX-4.3
19ox6uwqgfz
2 Jan 24
Automatic shelf registration
4:06pm